News from Tuesday, February 11, 2025
Articles
SLGT2s, GLP-1s Reduce Risk for COPD Exacerbations
(2/11, Andrew Rhoades, Healio) reports “...[T]he results suggest that either GLP-1 receptor agonists or SGLT2 inhibitors may be preferable over DPP-4 inhibitors ‘when deciding among glucose-lowering medications for patients with type 2 diabetes and active COPD,’ the researchers concluded.” Full
The End Of The MA Value-Based Insurance Design Model: What Next?
(2/11, Riya Doshi and A. Mark Fendrick, Health Affairs Forefront) comments “...Although the MA-VBID model will soon be discontinued, Congress and the second Trump Administration can build on V-BID policies implemented in the first Trump administration to lower out-of-pocket medical costs, such as the Health Savings Account-eligible High-Deductible Health Plans (IRS Notice 2019-45), which allowed coverage of 14 specific chronic disease services, including several medication classes, prior to beneficiaries meeting the plan deductible.” Full
Navigating the Unknown: EU HTA Regulation’s Impact on Commercial Confidentiality
(2/11, Eliza Slawther, Pink Sheet) reports “...Improving transparency is a key ambition of the EU Health Technology Assessment (HTA) Regulation, but it will also require manufacturers to plan their strategies around sharing confidential information carefully. This is according to experts from the pharmaceutical services provider Cencora, formerly known as AmerisourceBergen.” Subscription Required
Press Releases
Generative AI Set to Reshape Health Technology Assessment, ISPOR Report Finds
(2/11, ISPOR Press Release) “...‘Within the field of health economics and outcomes research, generative AI has the potential to transform HTA evidence generation methods,’ said author Jagpreet Chhatwal, PhD, Director of the Institute for Technology Assessment at Massachusetts General Hospital, Boston, United States. ‘Ensuring human oversight, transparency, and adherence to ethical standards is critical as we navigate this transformative era,’ noted Chhatwal, who is also an Associate Professor at Harvard Medical School and core faculty member of the Center for Health Decision Science at Harvard University.” Full
Two Recent Data Reports Show that PCORnet® May Potentially Power Impactful Research into Mental and Behavioral Health and Pediatric Populations
(2/11, PCORnet Press Release) “Two recent data reports are providing researchers and the public with insights into the PCORnet® infrastructure. These reports offer topic-specific snapshots of the extensive, real-world patient data available through PCORnet® Clinical Research Networks (CRNs), helping research teams to refine research questions, identify relevant data elements, and design more informed, impactful studies.” Full
Journals
Generative Artificial Intelligence for Health Technology Assessment: Opportunities, Challenges, and Policy Considerations: An ISPOR Working Group Report
Rachael L. Fleurence, PhD, et al.
February 2025, Value in Health
Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary Disease Exacerbations in Patients With Type 2 Diabetes
Avik Ray, MD, MS, et al.
February 10, 2025, JAMA Internal Medicine